Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
sharewise zieht um Am Wochenende vom 22./23. August wird das neue sharewise die Hauptseite. Schau es dir jetzt an und sag uns, was dir fehlt. Zum neuen sharewise Was sich ändert
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago. These

Zacks 
0 06.08.26
Denali Therapeutics Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, Janitorial service, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/4d4e885c-79e9-4b8f-bd91-e9721cd7c2e9.png
Denali Therapeutics Q2 Earnings Call Highlights

Key Points

MarketBeat 
0 07.08.26
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the

Zacks 
0 07.08.26
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Shares of Denali Therapeutics, Inc. DNLI have gained 33.1% in the last three months compared with the industry’s growth of 7.4%. The stock has outperformed the sector and the S&P 500 Index during

Zacks 
0 20.08.26